<DOC>
	<DOCNO>NCT01720849</DOCNO>
	<brief_summary>The aim study assess improvement visual evoke potential , cognition , fatigue , micturation walk impairment 3 month Fampyra treatment</brief_summary>
	<brief_title>Efficiency 4-aminopyridin ( Fampyra ) Gait , Vision , Cognition , Fatigue Micturation Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>All patient accord compound 's Norwegian prescription guideline deem eligible study , i.e . MS patient impair walk determine EDSS 47 . They need past history optic neuritis , cognitive failure , fatigue difficulty micturate . MS patient contraindication compound accord prescription guideline . Patients expose Fampyra past Patients MS attack within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>